REBOXETINE AND SSRIS

The manufacturers of reboxetine predict that potent inhibitors of CYP3A4 will reduce its metabolism. They name fluvoxamine, but note that fluvoxamine is more usually considered a potent inhibitor of CYP1A2 and is generally considered a weak inhibitor of CYP3A4.
The manufacturers say that concurrent use of fluvoxamine should be avoided.